Evidence map›Paper›PMID 38484531›Full record

ArticleThe International journal on drug policy2024

Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia.

Ahsan Ahmad, Daniel J Bromberg, Roman Shrestha, Na Mohd Salleh, Alexander R Bazazi, Adeeba Kamarulzaman, Sheela Shenoi, Frederick L Altice

Abstract read
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahsan AhmadYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Daniel J BrombergYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Yale University School of Public Health, Department of Social and Behavioral Sciences, New Haven, CT, USA.
Roman ShresthaUniversity of Connecticut, Department of Allied Health Sciences, Storrs, CT, USA.
Na Mohd SallehCentre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; University of Malaya, Faculty of Medicine, Department of Social and Preventive Medicine, Kuala Lumpur, Malaysia.
Alexander R BazaziYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA.
Adeeba KamarulzamanYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; University of Malaya, Faculty of Medicine, Department of Social and Preventive Medicine, Kuala Lumpur, Malaysia.
Sheela ShenoiYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Frederick L AlticeYale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Yale University School of Public Health, Department Epidemiology of Microbial Diseases, New Haven, CT, USA. Electronic address: frederick.altice@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Using Coincidence Analysis to Investigate Factors Affecting PrEP Initiation and Continuation in Southern ending the Epidemic CountiesP30MH062294 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 2001 to 2026
$48.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
INTERDISCIPLINARY HIV PREVENTION TRAINING PROGRAMT32MH020031 · NIMH · YALE UNIVERSITY · PI Trace S Kershaw · 1999 to 2026
$12.1M
Addiction, HIV and Tuberculosis in Malaysian Criminal Justice SettingsR01DA041271 · NIDA · YALE UNIVERSITY · PI SHENOI, SHEELA · 2016 to 2021
$3.3M
Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaR01DA025943 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2008 to 2012
$2.7M
Malaysian Implementation Science Training (MIST) Program in HIVD43TW011324 · FIC · YALE UNIVERSITY · PI FREDERICK LEWIS ALTICE, Rafdzah Zaki · 2020 to 2026
$1.8M
Enhancing Health Outcomes Among HIV+ Substance AbusersK24DA017072 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2003 to 2012
$1.5M
Improving Health Outcomes for Released HIV+ PrisonersR21DA019843 · NIDA · YALE UNIVERSITY · PI ALTICE, FREDERICK LEWIS · 2006 to 2007
$405k
Improving HIV and substance use disorder treatment research by integrating randomized and nonrandomized studies: an evaluation of methadone for HIV-infected opioid-dependent Malaysian prisoners.F30DA039716 · NIDA · YALE UNIVERSITY · PI BAZAZI, ALEXANDER REZA · 2015 to 2017
$123k
Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in UkraineF31DA054861 · NIDA · YALE UNIVERSITY · PI BROMBERG, DANIEL J · 2021 to 2023
$94k
FIC NIH HHS D43 TW010540FIC NIH HHS D43 TW011324NCATS NIH HHS UL1 TR001863NIDA NIH HHS F30 DA039716NIDA NIH HHS F31 DA054861NIDA NIH HHS K24 DA017072NIDA NIH HHS R01 DA025943NIDA NIH HHS R01 DA041271NIDA NIH HHS R21 DA019843NIGMS NIH HHS T32 GM007205NIMH NIH HHS P30 MH062294NIMH NIH HHS T32 MH020031
6 · The paper itself

Abstract

backgroundIncarcerated people with HIV and opioid-dependence often experience poor post-release outcomes in the absence of methadone maintenance treatment (MMT). In a prospective trial, we assessed the impact of methadone dose achieved within prison on linkage to MMT after release.

methodsFrom 2010 to 2014, men with HIV (N = 212) and opioid dependence before incarceration were enrolled in MMT within 6 months of release from Malaysia's largest prison and followed for 12-months post-release. As a prospective trial, allocation to MMT was at random and later by preference design (predictive nonetheless). MMT dosing was individually targeted to minimally achieve 80 mg/day. Time-to-event analyses were conducted to model linkage to MMT after release.

findingsOf the 212 participants allocated to MMT, 98 (46 %) were prescribed higher dosages (≥80 mg/day) before release. Linkage to MMT after release occurred in 77 (36 %) participants and significantly higher for those prescribed higher dosages (46% vs 28 %; p = 0.011). Factors associated with higher MMT dosages were being married, on antiretroviral therapy, longer incarceration periods, having higher levels of depression, and methadone preference compared to randomization. After controlling for other variables, being prescribed higher methadone dosage (aHR: 2.53, 95 %CI: 1.42-4.49) was the only independent predictor of linkage to methadone after release.

interpretationHigher doses of methadone prescribed before release increased the likelihood of linkage to MMT after release. Methadone dosing should be introduced into international guidelines for treatment of opioid use disorder in prisons and further post-release benefits should be explored.

fundingNational Institute of Drug Abuse (NIDA).

Indexed as

HIV InfectionsMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPrisonersAdultAnalgesics, OpioidDose-Response Relationship, DrugHumansMalaysiaMaleMiddle AgedPrisonsProspective StudiesAnalgesics, OpioidMethadoneMethadoneOpioid dependenceOptimal dosingPrisonRetention

Identifiers

PMID38484531
PMCPMC11056294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.